Cited by 1,608Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record; 16 of the 17 references it cites were found in a registry or an index.

A decade of immune-checkpoint inhibitors in cancer therapy

Open access

Robert, Caroline·2020·Nature Communications

DOI 10.1038/s41467-020-17670-yPMC PMC7393098

Open this paper in CoChat — free account Open PDF

Abstract

Immunotherapy using immune-checkpoint modulators revolutionizes the oncology field far beyond their remarkable clinical efficacy in some patients. It creates radical changes in the evaluation of treatment efficacy and toxicity with a more holistic vision of the patient with cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41467-020-17670-y

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citation
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,980
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3923 · Cited by 2,674
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30074-8 · Cited by 2,472
Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246
Adjuvant pembrolizumab versus placebo in resected stage III melanoma
Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802357 · Cited by 1,906
Self-citation
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Boutros, C., Tarhini, A. A., Routier, É., Lambotte, O., Ladurie, F. L. R., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,100
Self-citation

Show all 17 references

Sorted by citations

Immune Checkpoint Inhibitors in Cancer Therapy
Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., Ladwa, R., O’Byrne, K., & Kulasinghe, A. (2022) · Current Oncology · doi:10.3390/curroncol29050247 · Cited by 1,353
The Hippo signalling pathway and its implications in human health and diseases
Fu, M., Hu, Y., Lan, T., Guan, K., Luo, T., & Luo, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01191-9 · Cited by 823
Gut microbiota in colorectal cancer development and therapy
Wong, C. C., & Yu, J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00766-x · Cited by 779
Next generation of immune checkpoint inhibitors and beyond
Marin-Acevedo, J. A., Kimbrough, E. O., & Lou, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01056-8 · Cited by 574
Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics
Yamaguchi, H., Hsu, J.-M., Yang, W., & Hung, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00601-9 · Cited by 520
Photodynamic Therapy for the Treatment and Diagnosis of Cancer–A Review of the Current Clinical Status
Gunaydin, G., Gedik, M. E., & Ayan, S. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.686303 · Cited by 402
T Cell Exhaustion
Baessler, A., & Vignali, D. A. A. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-090222-110914 · Cited by 420
Lactate-Lactylation Hands between Metabolic Reprogramming and Immunosuppression
Chen, L., Huang, L., Gu, Y. L., Cang, W., Sun, P., & Xiang, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911943 · Cited by 380
The Role of Macrophages in Cancer Development and Therapy
Cendrowicz, E., Sas, Z., Bremer, E., & Rygiel, T. P. (2021) · Cancers · doi:10.3390/cancers13081946 · Cited by 332
Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer
Cords, L., Engler, S., Haberecker, M., Rüschoff, J. H., Moch, H., de Souza, N., & Bodenmiller, B. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.021 · Cited by 334
Neoantigen: A New Breakthrough in Tumor Immunotherapy
Zhang, Z., Lu, M., Qin, Y., Gao, W., Li, T., Su, W., & Zhong, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.672356 · Cited by 297
Cancer-Associated Fibroblasts in Inflammation and Antitumor Immunity
Kennel, K. B., Bozlar, M., Valk, A. F. D., & Greten, F. R. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1031 · Cited by 297
Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired
Marei, H. E. S., Hasan, A., Pozzoli, G., & Cenciarelli, C. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02902-0 · Cited by 269
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
Nicolò, E., Giugliano, F., Ascione, L., Tarantino, P., Corti, C., Tolaney, S. M., Cristofanilli, M., & Curigliano, G. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102395 · Cited by 243
Acute kidney injury in patients treated with immune checkpoint inhibitors
Gupta, S., Short, S., Sise, M. E., Prosek, J. M., Madhavan, S. M., Soler, M. J., Ostermann, M., Herrmann, S. M., Abudayyeh, A., Anand, S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003467 · Cited by 239
Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer
Virassamy, B., Caramia, F., Savas, P. S., Sant, S. A., Wang, J., Christo, S. N., Byrne, A., Clarke, K. A., Brown, E., Teo, Z. L., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.01.004 · Cited by 247
The Multifaceted Biology of PCSK9
Seidah, N. G., & Prat, A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab035 · Cited by 232
The KRAS-G12C inhibitor: activity and resistance
Liu, J., Kang, R., & Tang, D. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00383-9 · Cited by 229
Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study
Patil, V., Noronha, V., Menon, N. S., Rai, R., Bhattacharjee, A., Singh, A. K., Nawale, K. P., Jogdhankar, S., Tambe, R., Dhumal, S. B., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01015 · Cited by 221
The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
Güven, D. C., Şahin, T. K., Erul, E., Rizzo, A., Ricci, A. D., Aksoy, S., & Yalçın, Ş. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1039121 · Cited by 220
Cell Membrane-Coated Mimics: A Methodological Approach for Fabrication, Characterization for Therapeutic Applications, and Challenges for Clinical Translation
Chugh, V., Krishna, K. V., & Pandit, A. S. (2021) · ACS Nano · doi:10.1021/acsnano.1c03800 · Cited by 219
Immune Checkpoint Inhibitor Therapy in Oncology
Tan, S., Day, D., Nicholls, S. J., & Segelov, E. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.09.004 · Cited by 219
Unraveling the tumor microenvironment: Insights into cancer metastasis and therapeutic strategies
El‐Tanani, M., Rabbani, S. A., Babiker, R. A., Rangraze, I. R., Kapre, S., Palakurthi, S. S., Alnuqaydan, A. M., Aljabali, A. A. A., Rizzo, M., El‐Tanani, Y., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216894 · Cited by 212
Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors
Kovacs, S., Fekete, J. T., & Győrffy, B. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01079-6 · Cited by 206
Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies
Magré, L., Verstegen, M. M. A., Buschow, S. I., van der Laan, L. J. W., Peppelenbosch, M. P., & Desai, J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006290 · Cited by 201
Senescence as a therapeutic target in cancer and age-related diseases
McHugh, D., Durán, I., & Gil, J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01074-4 · Cited by 197
Neurological Manifestations of COVID-19 Feature T Cell Exhaustion and Dedifferentiated Monocytes in Cerebrospinal Fluid
Heming, M., Li, X., Räuber, S. J., Mausberg, A. K., Börsch, A., Hartlehnert, M., Singhal, A., Lu, I., Fleischer, M., Szepanowski, F., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.12.011 · Cited by 181
Chemo-Immunotherapy: A New Trend in Cancer Treatment
Sordo‐Bahamonde, C., Lorenzo‐Herrero, S., González, A. P., Martínez‐Pérez, A., Rodrigo, J. P., Garcia-Pedrero, J. M., & Gonzalez, S. R. (2023) · Cancers · doi:10.3390/cancers15112912 · Cited by 192
Tumor heterogeneity: preclinical models, emerging technologies, and future applications
Proietto, M., Crippa, M., Damiani, C., Pasquale, V., Sacco, E., Vanoni, M., & Gilardi, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1164535 · Cited by 188
Targeting macrophages in hematological malignancies: recent advances and future directions
Li, W., Wang, F., Guo, R., Bian, Z., & Song, Y. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01328-x · Cited by 174
The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study
Santoni, M., Rizzo, A., Mollica, V., Matrana, M. R., Rosellini, M., Faloppi, L., Marchetti, A., Battelli, N., & Massari, F. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103596 · Cited by 169
Interferon-stimulated neutrophils as a predictor of immunotherapy response
Benguigui, M., Cooper, T. J., Kalkar, P., Schif‐Zuck, S., Halaban, R., Bacchiocchi, A., Kamer, I., Deo, A., Manobla, B., Rottem, M., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.005 · Cited by 179
Roles of reactive oxygen species in inflammation and cancer
Yu, Y., Liu, S., Yang, L., Song, P., Liu, Z., Liu, X., Yan, X., & Dong, Q. (2024) · MedComm · doi:10.1002/mco2.519 · Cited by 180
Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma
Naghavian, R., Faigle, W., Oldrati, P., Wang, J., Toussaint, N. C., Qiu, Y., Medici, G., Wacker, M., Freudenmann, L. K., Bonté, P.-E., et al. (2023) · Nature · doi:10.1038/s41586-023-06081-w · Cited by 163
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study
Mollica, V., Rizzo, A., Marchetti, A., Tateo, V., Tassinari, E., Rosellini, M., Massafra, R., Santoni, M., & Massari, F. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01159-1 · Cited by 163
Modulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy
Kang, X., Lau, H. C.-H., & Yu, J. Q. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101478 · Cited by 172
A Noble AuPtAg‐GOx Nanozyme for Synergistic Tumor Immunotherapy Induced by Starvation Therapy‐Augmented Mild Photothermal Therapy
Wang, M., Chang, M., Zheng, P., Sun, Q., Wang, G., Lin, J., & Li, C. (2022) · Advanced Science · doi:10.1002/advs.202202332 · Cited by 157
The role of neutrophil extracellular traps in cancer progression and metastasis
Meo, M. L. D., & Spicer, J. D. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2022.101595 · Cited by 158
Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy
Gaikwad, S. R., Agrawal, M. Y., Kaushik, I., Ramachandran, S., & Srivastava, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.014 · Cited by 159
Bioadhesive injectable hydrogel with phenolic carbon quantum dot supported Pd single atom nanozymes as a localized immunomodulation niche for cancer catalytic immunotherapy
He, H., Fei, Z., Guo, T., Hou, Y., Li, D., Wang, K., Ren, F., Fan, K., Zhou, D., Xie, C., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121272 · Cited by 155
The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress
Sasso, J. M., Tenchov, R., Bird, R. E., Iyer, K. A., Ralhan, K., Rodríguez, Y., & Zhou, Q. A. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00374 · Cited by 162
Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study
Rizzo, A., Santoni, M., Mollica, V., Logullo, F. O., Rosellini, M., Marchetti, A., Faloppi, L., Battelli, N., & Massari, F. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.2029405 · Cited by 151
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis
Santoni, M., Rizzo, A., Kucharz, J., Mollica, V., Rosellini, M., Marchetti, A., Tassinari, E., Monteiro, F. S. M., Soares, A., Molina‐Cerrillo, J., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03349-4 · Cited by 151
Single-Site Nanozymes with a Highly Conjugated Coordination Structure for Antitumor Immunotherapy via Cuproptosis and Cascade-Enhanced T Lymphocyte Activity
Liu, Y., Niu, R., Zhao, H. Q., Wang, Y., Song, S., Zhang, H., & Zhao, Y. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.3c08622 · Cited by 146
Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review
Jayathilaka, B., Mian, F., Franchini, F., Au‐Yeung, G., & IJzerman, M. J. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02887-1 · Cited by 166
iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting
Goldenson, B. H., Hor, P., & Kaufman, D. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.841107 · Cited by 154
Cardiovascular complications of immune checkpoint inhibitors for cancer
Thuny, F., Naidoo, J., & Neilan, T. G. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac456 · Cited by 142
Interpretable systems biomarkers predict response to immune-checkpoint inhibitors
Lapuente-Santana, Ó., van Genderen, M. N. G., Hilbers, P. A. J., Finotello, F., & Eduati, F. (2021) · Patterns · doi:10.1016/j.patter.2021.100293 · Cited by 142
Extracellular Vesicles in Liquid Biopsies as Biomarkers for Solid Tumors
Irmer, B., Chandrabalan, S., Maas, L., Bleckmann, A., & Menck, K. (2023) · Cancers · doi:10.3390/cancers15041307 · Cited by 137
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours
Melero, I., Luken, M. D. M., de Velasco, G., Garralda, E., Martín-Liberal, J., Joerger, M., Alonso, G., Goebeler, M.-E., Schüler, M., König, D., et al. (2024) · Nature · doi:10.1038/s41586-024-08305-z · Cited by 144
British Gynaecological Cancer Society (BGCS) uterine cancer guidelines: Recommendations for practice
Morrison, J., Balega, J., Buckley, L., Clamp, A. R., Crosbie, E. J., Drew, Y., Durrant, L., Forrest, J., Fotopoulou, C., Gajjar, K. B., et al. (2021) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2021.11.423 · Cited by 133
Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives
Peyraud, F., Guégan, J., Bodet, D., Cousin, S., Bessede, A., & Italiano, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.807271 · Cited by 137
Harnessing the chemokine system to home CAR-T cells into solid tumors
Foeng, J., Comerford, I., & McColl, S. R. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100543 · Cited by 133
Small-molecule GSDMD agonism in tumors stimulates antitumor immunity without toxicity
Fontana, P., Du, G., Zhang, Y., Zhang, H., Vora, S. M., Hu, J. J., Shi, M., Tufan, A. B., Healy, L. B., Xia, S., et al. (2024) · Cell · doi:10.1016/j.cell.2024.08.007 · Cited by 134
Cancer Resistance to Immunotherapy: Comprehensive Insights with Future Perspectives
Said, S. S., & Ibrahim, W. N. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041143 · Cited by 134
Recent Advances in Molecular Mechanisms of Cancer Immunotherapy
Kciuk, M., Yahya, E. B., Mohamed, M. M. I., Rashid, S., Iqbal, M. O., Kontek, R., Abdulsamad, M. A., & Allaq, A. A. (2023) · Cancers · doi:10.3390/cancers15102721 · Cited by 135
T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
Gainor, J. F., Patel, M. R., Weber, J. S., Gutierrez, M., Bauman, J. E., Clarke, J. M., Julian, R., Scott, A. J., Geiger, J. L., Kirtane, K., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0158 · Cited by 124
Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors
Nassar, A. H., Adib, E., Abou Alaiwi, S., El Zarif, T., Groha, S., Akl, E. W., Nuzzo, P. V., Mouhieddine, T. H., Perea-Chamblee, T., Taraszka, K., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.022 · Cited by 121
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
Wei, J., Li, W., Zhang, P., Guo, F., & Liu, M. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02179-5 · Cited by 144
Nano-drug delivery system targeting tumor microenvironment: A prospective strategy for melanoma treatment
Xu, M., & Li, S. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216397 · Cited by 121
The Current Landscape of NKT Cell Immunotherapy and the Hills Ahead
Nelson, A., Lukacs, J., & Johnston, B. (2021) · Cancers · doi:10.3390/cancers13205174 · Cited by 124
Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action
Olivier, T., Haslam, A., & Prasad, V. K. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.38793 · Cited by 118
Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4
Pandey, P., Khan, F., Qari, H. A., Upadhyay, T. K., Alkhateeb, A. F., & Oves, M. (2022) · Pharmaceuticals · doi:10.3390/ph15030335 · Cited by 122
Regulatory T cells in the tumour microenvironment
Imianowski, C. J., Chen, Q., Workman, C. J., & Vignali, D. A. A. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00832-9 · Cited by 144
Senescence drives immunotherapy resistance by inducing an immunosuppressive tumor microenvironment
Maggiorani, D., Lê, O., Lisi, V., Landais, S., Moquin‐Beaudry, G., Lavallée, V., Decaluwe, H., & Beausejour, C. M. (2024) · Nature Communications · doi:10.1038/s41467-024-46769-9 · Cited by 130
Cardio-Oncology and Heart Failure: a Scientific Statement From the Heart Failure Society of America
Bloom, M. W., Vo, J. B., Rodgers, J. E., FERRARI, A. M., Nohria, A., Deswal, A. M., Cheng, R. K.-H., Kittleson, M. M., Upshaw, J. N., Palaskas, N. L., et al. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.08.045 · Cited by 128
Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment
Garg, P. K., Pareek, S., Kulkarni, P., Horne, D., Salgia, R., & Singhal, S. S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216537 · Cited by 131
Towards efficient immunotherapy for bacterial infection
McCulloch, T. R., Wells, T. J., & Souza-Fonseca-Guimarães, F. (2021) · Trends in Microbiology · doi:10.1016/j.tim.2021.05.005 · Cited by 116
Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer
Yin, X., Liao, H., Hong, Y., Lin, N., Li, S., Xiang, Y., & Ma, X. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.002 · Cited by 113
Assessing the future of solid tumor immunotherapy
Guha, P., Heatherton, K. R., O’Connell, K. P., Alexander, I. S., & Katz, S. C. (2022) · Biomedicines · doi:10.3390/biomedicines10030655 · Cited by 105
British Gynaecological Cancer Society (BGCS) cervical cancer guidelines: Recommendations for practice
Reed, N., Balega, J., Barwick, T. D., Buckley, L., Burton, K., Eminowicz, G., Forrest, J., Ganesan, R., Harrand, R. L., Holland, C. M., et al. (2020) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2020.08.020 · Cited by 103
WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape
Lu, C., Liu, Z., Klement, J. D., Yang, D., Merting, A. D., Poschel, D. B., Albers, T., Waller, J. L., Shi, H., & Liu, K. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002624 · Cited by 103
MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways
Touchaei, A. Z., & Vahidi, S. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03293-6 · Cited by 102
Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis
Vitale, E., Rizzo, A., Maistrello, L., Güven, D. C., Massafra, R., Mollica, V., Monteiro, F. S. M., Santoni, M., & Massari, F. (2024) · Scientific Reports · doi:10.1038/s41598-024-71746-z · Cited by 104
Enhancing immuno-oncology investigations through multidimensional decoding of tumor microenvironment with IOBR 2.0
Zeng, D., Fang, Y., Qiu, W., Luo, P., Wang, S., Shen, R., Gu, W., Huang, X., Mao, Q., Wang, G., et al. (2024) · Cell Reports Methods · doi:10.1016/j.crmeth.2024.100910 · Cited by 111
Advances in dendritic cell vaccination therapy of cancer
Najafi, S., & Mortezaee, K. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114954 · Cited by 103
Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review
Garutti, M., Lambertini, M., & Puglisi, F. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100276 · Cited by 101
Systematic Investigation of Tumor Microenvironment and Antitumor Immunity With IOBR
Fang, Y., Kong, Y., Rong, G., Luo, Q., Liao, W., & Zeng, D. (2025) · Med Research · doi:10.1002/mdr2.70001 · Cited by 97
Correction of age-associated defects in dendritic cells enables CD4+ T cells to eradicate tumors
Zhivaki, D., Kennedy, S. N., Park, J., Borriello, F., Devant, P., Cao, A., Bahleda, K. M., Murphy, S. M., Aubin, C., Evavold, C. L., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.026 · Cited by 102
Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling
Solimando, A. G., Summa, S. D., Vacca, A., & Ribatti, D. (2020) · Cancers · doi:10.3390/cancers12113380 · Cited by 93
LAG3 ectodomain structure reveals functional interfaces for ligand and antibody recognition
Ming, Q., Celias, D. P., Wu, C., Cole, A. R., Singh, S., Mason, C. C., Dong, S., Tran, T. H., Amarasinghe, G. K., Ruffell, B., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01238-7 · Cited by 92
Targeting pyroptosis for cancer immunotherapy: mechanistic insights and clinical perspectives
Huang, C. L., Li, J., Wu, R., Li, Y., & Zhang, C. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02344-4 · Cited by 116
Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity
Farina, A., Birzu, C., Elsensohn, M., Pïcca, A., Muñiz‐Castrillo, S., Vogrig, A., Villagrán‐García, M., Ciano-Petersen, N. L., Massacesi, L., Hervier, B., et al. (2023) · Brain Communications · doi:10.1093/braincomms/fcad169 · Cited by 93
Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond
Mosca, M., Nigro, M. C., Pagani, R., Giglio, A. D., & Federico, A. D. (2023) · Biomolecules · doi:10.3390/biom13121803 · Cited by 100
Macrophage Repolarization as a Therapeutic Strategy for Osteosarcoma
Anand, N., Peh, K. H., & Kolesar, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032858 · Cited by 94
Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment
Javadrashid, D., Baghbanzadeh, A., Derakhshani, A., Leone, P., Silvestris, N., Racanelli, V., Solimando, A. G., & Baradaran, B. (2021) · Biomedicines · doi:10.3390/biomedicines9040373 · Cited by 90
The difficulty in translating the preclinical success of combined TGFβ and immune checkpoint inhibition to clinical trial
Metropulos, A. E., Munshi, H. G., & Principe, D. R. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.104380 · Cited by 81
Melanoma: Molecular genetics, metastasis, targeted therapies, immunotherapies, and therapeutic resistance
Wagstaff, W., Mwamba, R. N., Grullon, K., Armstrong, M. L., Zhao, P., Hendren-Santiago, B. K., Qin, K. H., Li, A. J., Hu, D. A., Youssef, A., et al. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.04.004 · Cited by 94
Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives
Maiorano, B. A., Maiorano, M. F. P., Lorusso, D., & Maiello, E. (2021) · Cancers · doi:10.3390/cancers13174438 · Cited by 84
Chemotherapy induces myeloid-driven spatially confined T cell exhaustion in ovarian cancer
Launonen, I.-M. P., Niemiec, I., Hincapié-Otero, M. M., Erkan, E. P., Junquera, A., Afenteva, D., Falco, M. M., Liang, Z., Salko, M., Chamchougia, F., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.11.005 · Cited by 103
Immunocompetent cancer-on-chip models to assess immuno-oncology therapy
Maulana, T. I., Kromidas, E., Wallstabe, L., Cipriano, M., Alb, M., Zaupa, C., Hudecek, M., Fogal, B., & Loskill, P. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.015 · Cited by 86
Nanoscale Zeolitic Imidazolate Framework (ZIF)–8 in Cancer Theranostics: Current Challenges and Prospects
Xie, H., Liu, X., Huang, Z., Xu, L., Bai, R., He, F., Wang, M., Han, L., Bao, Z., Wu, Y., et al. (2022) · Cancers · doi:10.3390/cancers14163935 · Cited by 85
Anal Cancer: The Past, Present and Future
Gondal, T., Chaudhary, N., Bajwa, H., Rauf, A., Le, D., & Ahmed, S. (2023) · Current Oncology · doi:10.3390/curroncol30030246 · Cited by 89
Immunotherapy and immunoevasion of colorectal cancer
Zein, M. A., Boukhdoud, M., Shammaa, H., Mouslem, H., Ayoubi, L. M. E., Iratni, R., Issa, K., Khachab, M. Y., Assi, H. I., Sahebkar, A., et al. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103669 · Cited by 88
Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review
Barron, C. C., Stefanova, I. Z., Cha, Y., Elsolh, K., Zereshkian, A., Gaafour, N., & McWhirter, E. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006500 · Cited by 85
Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment
Kleinendorst, S. C., Oosterwijk, E., Bussink, J., Westdorp, H., Konijnenberg, M., & Heskamp, S. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4332 · Cited by 83
Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota
Fidelle, M., Yonekura, S., Picard, M., Cogdill, A. P., Hollebecque, A., Roberti, M. P., & Zitvogel, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.600886 · Cited by 87
Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study
Lee, P. Y., Oen, K. Q. X., Lim, G. R. S., Hartono, J. L., Muthiah, M. D., Huang, D. Q., Teo, F. S. W., Li, A., Mak, A., Chandran, N. S., et al. (2021) · Cancers · doi:10.3390/cancers13061308 · Cited by 87
Near Infrared Photoimmunotherapy; A Review of Targets for Cancer Therapy
Kato, T., Wakiyama, H., Furusawa, A., Choyke, P. L., & Kobayashi, H. (2021) · Cancers · doi:10.3390/cancers13112535 · Cited by 84
The immune modifying effects of chemotherapy and advances in chemo-immunotherapy
Principe, D. R., Kamath, S. D., Korc, M., & Munshi, H. G. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108111 · Cited by 83

Authors: Robert, C.
Affiliations: Institut Gustave Roussy (FR)
Corresponding author: Robert, Caroline
ORCID: Robert, Caroline
Venue: Nature Communications
Publisher: Springer Science and Business Media LLC
Published: 2020-07-30
Volume: 11
Issue: 1
Pages: 3801-3801
ISSN: 2041-1723 (ISSN-L)
DOI: 10.1038/s41467-020-17670-y
PMC: PMC7393098
OpenAlex: W3045946240
Cited by: 1,608
References: 17
Citations by year: 2026: 154 · 2025: 250 · 2024: 312 · 2023: 339 · 2022: 315 · 2021: 227 · 2020: 9
FWCI: 80.61
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0 (tdm)
creativecommons.org/licenses/by/4.0 (vor)
Locations: Nature Communications (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
HAL (submittedVersion)
RePEc: Research Papers in Economics (submittedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: immune checkpoint inhibitors, cancer immunotherapy, treatment efficacy assessment, immunotherapy toxicity, patient-centered care
MeSH terms: Antineoplastic Agents, Immunological, Ipilimumab, Nivolumab, Antibodies, Monoclonal, Humans, Immunotherapy, Neoplasms, B7-H1 Antigen, CTLA-4 Antigen, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A decade of immune-checkpoint inhibitors in cancer therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks